摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-pentyl-oxazole | 77311-05-8

中文名称
——
中文别名
——
英文名称
2-pentyl-oxazole
英文别名
2-Pentyl-oxazol;2-Pentyloxazole;2-pentyl-1,3-oxazole
2-pentyl-oxazole化学式
CAS
77311-05-8
化学式
C8H13NO
mdl
——
分子量
139.197
InChiKey
TWTMHOPOBRKCKX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    172-173 °C
  • 密度:
    0.941±0.06 g/cm3(Predicted)
  • LogP:
    2.300 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    10
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    26
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS<br/>[FR] POTENTIEL THÉRAPEUTIQUE ÉTENDU DANS DES ANTIMICROBIENS À NITROHÉTÉROARYLE
    申请人:UNIV CALIFORNIA
    公开号:WO2014205414A1
    公开(公告)日:2014-12-24
    Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to imidazole, thiazole, and furan derivatives and their use as therapeutic agents.
    本文披露了抗微生物化合物组合物、药物组合物及其使用和制备。一些实施例涉及咪唑噻唑呋喃生物及其作为治疗剂的用途。
  • N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
    申请人:Rodgers James D.
    公开号:US20100298334A1
    公开(公告)日:2010-11-25
    The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及式I的N-(杂)芳基吡咯烷衍生物: 这些是JAK抑制剂,如选择性JAK1抑制剂,在治疗JAK相关疾病方面具有用处,例如炎症和自身免疫性疾病,以及癌症。
  • Oxazole derivatives
    申请人:——
    公开号:US20030055265A1
    公开(公告)日:2003-03-20
    The present invention relates to novel oxazole compounds which act as PPAR&agr; and PPAR&ggr; agonists and are accordingly useful for the treatment of diseases modulated by PPAR&agr; and PPAR&ggr; such as diabetes.
    本发明涉及新型噁唑化合物,其作为PPAR&agr;和PPAR&ggr;激动剂,并因此可用于治疗由PPAR&agr;和PPAR&ggr;调节的疾病,如糖尿病。
  • 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
    申请人:Neustadt R. Bernard
    公开号:US20070066620A1
    公开(公告)日:2007-03-22
    Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R 1 -isoxazolyl, R 1 -oxadiazolyl, R 1 -dihydrofuranyl, R 1 -pyrazolyl, R 1 -imidazolyl, R 1 -pyrazinyl or R 1 -pyrimidinyl; R 1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.
    具有结构式I或其药用可接受盐的化合物,其中R是R1-异噁唑基、R1-噁唑啉基、R1-二氢呋喃基、R1-吡唑基、R1-咪唑基、R1-吡啶基或R1-嘧啶基;R1是从H、烷基、烷氧基和卤代中选择的1、2或3个取代基;Z是可选择取代的芳基或可选择取代的杂芳基;公开了这些化合物及其在治疗中枢神经系统疾病,特别是帕森病和额外锥体综合征中的用途,包括它们的药物组合物和与其他药剂的组合。
  • 5-HT2B receptor antagonists
    申请人:Oxford William Alexander
    公开号:US20050176791A1
    公开(公告)日:2005-08-11
    The present invention relates to compounds which include compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein one of R 1 and R 4 is selected from the group consisting of H, and optionally substituted C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkyl, and phenyl-C 1-4 alkyl; and the other of R 1 and R 4 is an optionally substituted C 9-14 aryl group; R 2 and R 3 are either: (i) independently selected from H, R, R′, SO 2 R, C(═O)R, (CH 2 ) n NR 5 R 6 , where n is from 1 to 4 and R 5 and R 6 are independently selected from H and R, where R is optionally substituted C 1-4 alkyl, and R′ is optionally substituted phenyl-C 1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C 5-7 heterocyclic group. The compounds are useful in the treatment of conditions including conditions which can be alleviated by antagonism of a 5-HT 2B receptor such as GI disorders and congestive heart failure.
    本发明涉及包括公式I化合物的化合物:或其药用可接受的盐,其中R1和R4之一选自由H、以及可选地取代的C1-6烷基、C3-7环烷基、C3-7环烷基-C1-4烷基和苯基-C1-4烷基组成的组;而R1和R4中的另一个是可选地取代的C9-14芳基基团;R2和R3是:(i)独立地选自H、R、R′、SO2R、C(═O)R、(CH2)nNR5R6,其中n是从1到4,而R5和R6独立地选自H和R,其中R是可选地取代的C1-4烷基,而R′是可选地取代的苯基-C1-4烷基,或(ii)与它们所连接的氮原子一起,形成一个可选地取代的C5-7杂环基团。这些化合物可用于治疗包括可以通过对抗5-HT2B受体而缓解的条件,如胃肠道疾病和充血性心力衰竭。
查看更多